Unrestricted Medicaid Access to Novel Hepatitis C Therapies May Reduce Overall Costs

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the publication of an empirical study demonstrating that current Medicaid policies restricting hepatitis C treatment to patients with advanced disease are more costly and less effective than unrestricted, full-access strategies. The results of this novel research, “Economic and Public …
(continue reading)

Article source: https://health.einnews.com/article_detail/332961011/ddJQ4I3B4AgYWWYB?ref=rss&ecode=uiQ1mLaH2KVPSS4e